Article Menu
Need Help?
No Article Versions Notes Found
Cite
Aiello, A.; Mariano, E.E.; Prada, M.; Teruzzi, C.; Martone, N.; Capri, S.; Carli, G.; Siragusa, S. Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments. J. Mark. Access Health Policy 2023, 11, 2230663. https://doi.org/10.1080/20016689.2023.2230663
Aiello A, Mariano EE, Prada M, Teruzzi C, Martone N, Capri S, Carli G, Siragusa S. Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments. Journal of Market Access & Health Policy. 2023; 11(1):2230663. https://doi.org/10.1080/20016689.2023.2230663
Chicago/Turabian StyleAiello, Andrea, Elisa Elena Mariano, Mariangela Prada, Cristina Teruzzi, Nicoletta Martone, Stefano Capri, Giuseppe Carli, and Sergio Siragusa. 2023. "Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments" Journal of Market Access & Health Policy 11, no. 1: 2230663. https://doi.org/10.1080/20016689.2023.2230663
APA StyleAiello, A., Mariano, E. E., Prada, M., Teruzzi, C., Martone, N., Capri, S., Carli, G., & Siragusa, S. (2023). Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments. Journal of Market Access & Health Policy, 11(1), 2230663. https://doi.org/10.1080/20016689.2023.2230663
